Role of Soluble T-Cell Immunoglobulin Mucin Domain-3 in Differentiating Nontuberculous Mycobacterial Lung Disease from Pulmonary Colonization

Pan, Shiann; Lee, Chang-Ching; Feng, Jia-Yih; Chan, Yu‐Jiun; Chen, Yuh‐Min; Su, Wei‐Juin

doi:10.1016/j.arbres.2021.01.035

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improving microbiological methods and added number of vulnerable patients, has added Nocardia spp., fungi and environmental mycobacteria to the spectrum of potential pathogens. Recent advances include guidelines to assess definitions of disease stages for environmental mycobacteria [39][40][41] and also for pulmonary aspergillosis, depending on the interaction between Aspergillus and the host [27].…”

Section: Spectrum Of Diseasementioning

confidence: 99%

Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms?

Stojanović

Gonçalves-Carvalho²,

Marín³

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

Respiratory tract infections (RTI) are one of the commonest reasons for seeking healthcare, but are amongst the most challenging diseases in terms of clinical decision making. Proper and timely diagnosis is critical in order to optimize management and prevent further emergence of antimicrobial resistance by misuse, or overuse of antibiotics. Diagnostic tools for RTI include those involving syndromic and etiological diagnosis: from clinical and radiological features to laboratory methods targeting both pathogen detection and host biomarkers, as well as their combinations in terms of clinical algorithms. They also include tools for predicting severity and monitoring treatment response. Unprecedented milestones have been achieved in the context of the COVID-19 pandemic, involving the most recent applications of diagnostic technologies both at genotypic and phenotypic level, which have changed paradigms in infectious respiratory diseases in terms of why, how and where diagnostics are performed. The aim of this review is to discuss advances in diagnostic tools that impact clinical decision making, surveillance and follow-up of RTI and tuberculosis. If properly harnessed, recent advances in diagnostic technologies, including omics and digital transformation emerge as an unprecedented opportunity to tackle ongoing and future epidemics while handling antimicrobial resistance from a One Health perspective.

show abstract

Section: Spectrum Of Diseasementioning

confidence: 99%

Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms?

Stojanović

Gonçalves-Carvalho²,

Marín³

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

show abstract

“…Asymptomatic persons with a history of close contact in the past six months with another PTB patient (prior to enrollment) were included if they had normal chest radiography and IGRA-positivity, indicating LTBI ( 26 ). As comparators, patients with NTM-LD were enrolled if they had positive NTM cultures from respiratory samples and met the NTM-LD diagnostic criteria for active disease ( 27 , 28 ). The exclusion criteria were 1) HIV infection in PTB patients tested at enrollment and in NTM-LD patients assessed by reviewing claim data, 2) concomitant active cancer, and 3) mixed MTB and NTM-LD infection.…”

Section: Methodsmentioning

confidence: 99%

Circulating mitochondrial cell-free DNA dynamics in patients with mycobacterial pulmonary infections: Potential for a novel biomarker of disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

ObjectivesHuman mitochondrial cell-free DNA (Mt-cfDNA) may serve as a useful biomarker for infectious processes. We investigated Mt-cfDNA dynamics in patients with pulmonary mycobacterial infections to determine if this novel biomarker could be used to differentiate disease states and severity.MethodsPatients with pulmonary tuberculosis (PTB), latent tuberculosis infection (LTBI), and nontuberculous mycobacterial-lung disease (NTM-LD) were enrolled at a tertiary care hospital in Taiwan between June 2018 and August 2021. Human Mt-cfDNA and nuclear-cfDNA (Nu-cfDNA) copy numbers were estimated by quantitative polymerase chain reaction. Variables associated with PTB and 2-month sputum culture-positivity, indicating poor treatment response, were assessed using logistic regression.ResultsAmong 97 patients with PTB, 64 with LTBI, and 51 with NTM-LD, Mt-cfDNA levels were higher in patients with PTB than in LTBI (p=0.001) or NTM-LD (p=0.006). In the Mycobacterium tuberculosis-infected population, Mt-cfDNA levels were highest in smear-positive PTB patients, followed by smear-negative PTB (p<0.001), and were lowest in LTBI persons (p=0.009). A Mt-cfDNA, but not Nu-cfDNA, level higher than the median helped differentiate culture-positive PTB from culture-negative PTB and LTBI (adjusted OR 2.430 [95% CI 1.139–5.186], p=0.022) and differentiate PTB from NTM-LD (adjusted OR 4.007 [1.382–12.031], p=0.011). Mt-cfDNA levels decreased after 2 months of treatment in PTB patients (p=0.010). A cutoff Mt-cfDNA level greater than 62.62 x 106 copies/μL-plasma was associated with a 10-fold risk of 2-month culture-positivity (adjusted OR 9.691 [1.046–89.813], p=0.046).ConclusionElevated Mt-cfDNA levels were associated with PTB disease and failed sputum conversion at 2 months in PTB patients, and decreased after treatment.

show abstract

Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases

Bailly

Thuru

Goossens

et al. 2023

Biochemical Pharmacology

View full text Add to dashboard Cite

Role of Soluble T-Cell Immunoglobulin Mucin Domain-3 in Differentiating Nontuberculous Mycobacterial Lung Disease from Pulmonary Colonization

Cited by 4 publications

References 31 publications

Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms?

Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms?

Circulating mitochondrial cell-free DNA dynamics in patients with mycobacterial pulmonary infections: Potential for a novel biomarker of disease

Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases

Contact Info

Product

Resources

About